Trial record 21 of 33 for: "multiple sclerosis" | "vitamin d"
Zoledronic Acid in MS-patients With Osteoporosis (EXALT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01166178|
Recruitment Status : Terminated
First Posted : July 20, 2010
Results First Posted : November 26, 2013
Last Update Posted : November 26, 2013
Information provided by (Responsible Party):
|Study Design||Allocation: Randomized; Intervention Model: Single Group Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment|
Drug: Zoledronic Acid
Dietary Supplement: Calcium and Vitamin D combination
|Recruitment Details||168 participants were planned to be randomized. 29 participants were randomized in a 2:1 ratio (zoledronic acid : placebo); no participants completed the study. One participant withdrew consent and the study was terminated.|
Study termination due to small number of participants recruited lead to lack of power for analysis of all outcome measures.